Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 0.21.

  • Insight Molecular Diagnostics' Equity Ratio fell 25133.55% to 0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.21, marking a year-over-year decrease of 25133.55%. This contributed to the annual value of 0.35 for FY2024, which is 22801.89% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Equity Ratio stood at 0.21, which was down 25133.55% from 0.02 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Equity Ratio registered a high of 0.82 during Q1 2021, and its lowest value of 0.35 during Q4 2024.
  • For the 5-year period, Insight Molecular Diagnostics' Equity Ratio averaged around 0.3, with its median value being 0.34 (2022).
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 3397.3% in 2021, then plummeted by 25133.55% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Equity Ratio (Quarter) stood at 0.41 in 2021, then dropped by 16.18% to 0.34 in 2022, then dropped by 20.23% to 0.27 in 2023, then tumbled by 228.02% to 0.35 in 2024, then skyrocketed by 40.18% to 0.21 in 2025.
  • Its Equity Ratio was 0.21 in Q3 2025, compared to 0.02 in Q2 2025 and 0.17 in Q1 2025.